Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Equity Average (2020 - 2025)

Insight Molecular Diagnostics' Equity Average history spans 6 years, with the latest figure at -$4.0 million for Q3 2025.

  • For Q3 2025, Equity Average fell 124.98% year-over-year to -$4.0 million; the TTM value through Sep 2025 reached -$4.0 million, down 124.98%, while the annual FY2024 figure was $4.1 million, 85.04% down from the prior year.
  • Equity Average for Q3 2025 was -$4.0 million at Insight Molecular Diagnostics, down from $5.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $104.6 million in Q2 2021 and bottomed at -$4.0 million in Q3 2025.
  • The 5-year median for Equity Average is $39.9 million (2023), against an average of $43.1 million.
  • The largest annual shift saw Equity Average soared 174.6% in 2021 before it crashed 124.98% in 2025.
  • A 5-year view of Equity Average shows it stood at $82.3 million in 2021, then crashed by 32.46% to $55.6 million in 2022, then crashed by 49.07% to $28.3 million in 2023, then tumbled by 104.53% to -$1.3 million in 2024, then crashed by 215.96% to -$4.0 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Equity Average are -$4.0 million (Q3 2025), $5.7 million (Q2 2025), and -$1.0 million (Q1 2025).